EcoDrugPlus

Proteasome 20s Subunit Alpha 2a

Ensembl ID : ENSACIG00000019925
Gene Symbol: PSMA2A
1 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSACIG00000021909
Gene Symbol: PSMA3
1 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSACIG00000013719
Gene Symbol: PSMA4
2 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSACIG00000000259
Gene Symbol: PSMA5
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6a

Ensembl ID : ENSACIG00000014595
Gene Symbol: PSMA6A
1 Cross references
229 Possible Orthologues:

Proteasome 20s Subunit Alpha 6b

Ensembl ID : ENSACIG00000012940
Gene Symbol: PSMA6B
1 Cross references
262 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSACIG00000016049
Gene Symbol: PSMA8
1 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSACIG00000007670
Gene Symbol: PSMB1
1 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSACIG00000016030
Gene Symbol: PSMB10
1 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSACIG00000000581
Gene Symbol: PSMB11B
1 Cross references
161 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSACIG00000014995
Gene Symbol: PSMB2
1 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSACIG00000024147
Gene Symbol: PSMB3
1 Cross references
261 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).